Approved Drug Products with therapeutic Equivalency

Electronic Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations, [Internet]. URL http //www.fda.gov/cder/ob/default.htm, accessed 7-29-2000. 

Orange Book means the FDA s publication entitled Approved Drug Products with Therapeutic Equivalence, in which the patents claiming a drug product approved through an NDA are listed. 

See FDA, Prefece to Twenty First Edition of Approved Drug Products with Therapeutic Equivalence Evaluation,... 

In an effort to codify bioequivalence information, the FDA publishes Approved Drug Products With Therapeutic Equivalence Evaluations, with monthly supplements, commonly called "the Orange Book." The book contains listings of multisource products in one of two categories Products coded "A" are considered bioequivalent to all other versions of that product with a similar "A" coding. Products not considered bioequivalent are coded "B." Of the approximately 8000 products listed, 90% are coded "A."... 

Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations and any current supplement to the publication. 

Generic products tested by the FDA and determined to be therapeutic equivalents are listed by the FDA in their publication Approved Drug Products with Therapeutic Equivalence Evaluations. These products contain the same active ingredients as their brand-name counterparts and also meet bioequivalence standards. The FDA recommends substitution only among products listed as therapeutically equivalent. 

Knoben, J.E. Scott, G.R. Tonelli, R.J. Overview of the FDA publication approved drug products with therapeutic equivalence evaluations. Am. J. Hosp. Pharm. 1990,47 (12),... 

The Electronic Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations. US Department of Health and Human Services, PubUc Health Service, Food and Dmg Administration, Center for Dmg Evaluation and Research (CDER), Office of Information Technology, Division of Data Management and Services. http //www. fda.gov/cder/ob/default.htm... 

In lieu of a summary, information should be provided that shows the proposed product is the same as a listed product (eligible products are listed in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations ) with respect to its indications for use, active ingredients, route of administration, dosage form, strength, bioavailability, and labeling. Patent certification information and any indications for... 

Approved Drug products with Therapeutic Equivalence Evaluations. US Department of Health and Human Services, Rockville, MD, annual updated by monthly supplements. 

Bioequivalence studies are the basis for determination of the therapeutic equivalence between a pharmaceutically equivalent generic drug product and a corresponding reference hsted drug. This hst is provided in the book titled Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. °... 

The reference standard in a bioequivalence study is a formulation currently marketed with an approved full NDA, for which there are valid scientific safety and efficacy data. The list of reference products is provided in the Orange Book ( Approved Drug Product with Therapeutic Equivalence Evaluations ). The reference product is usually the innovator s brand-name product. The total content of the active drug substance in the test product must be within 5% of the reference product. Usually similar routes of administration are used for the test and reference products unless an alternative route is needed to answer specific pharmacokinetic questions. In some cases the reference material could be a solution, suspension, IV product, or the clinical trial material containing the same quantity of active drug ingredient. 

---